WO2005110455A3 - Combination therapy for treating hepatitis virus infection - Google Patents

Combination therapy for treating hepatitis virus infection Download PDF

Info

Publication number
WO2005110455A3
WO2005110455A3 PCT/US2005/016353 US2005016353W WO2005110455A3 WO 2005110455 A3 WO2005110455 A3 WO 2005110455A3 US 2005016353 W US2005016353 W US 2005016353W WO 2005110455 A3 WO2005110455 A3 WO 2005110455A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
reducing
infection
combination therapy
individual
Prior art date
Application number
PCT/US2005/016353
Other languages
French (fr)
Other versions
WO2005110455A2 (en
Inventor
Osman N Ozes
Scott D Seiwert
Lawrence M Blatt
Original Assignee
Intermune Inc
Osman N Ozes
Scott D Seiwert
Lawrence M Blatt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc, Osman N Ozes, Scott D Seiwert, Lawrence M Blatt filed Critical Intermune Inc
Priority to CA002566677A priority Critical patent/CA2566677A1/en
Publication of WO2005110455A2 publication Critical patent/WO2005110455A2/en
Publication of WO2005110455A3 publication Critical patent/WO2005110455A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of treating a viral infection, e.g., a hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV infection and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a viral infection, e.g., an HCV infection. The methods generally involve administering to the individual i) a stress-activated protein kinase inhibitor; and ii) a Type I interferon receptor agonist. The present invention provides a method of treating alcoholic liver disease, the method involving administering to an individual in need thereof an effective amount of a stress-activated protein kinase (SAPK) inhibitor, alone or in combination therapy. The present invention further provides methods for treating non-alcoholic steatohepatitis, the method generally involving administering to an individual in need thereof an effective amount of a SAPK inhibitor, alone or in combination therapy.
PCT/US2005/016353 2004-05-13 2005-05-09 Combination therapy for treating hepatitis virus infection WO2005110455A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002566677A CA2566677A1 (en) 2004-05-13 2005-05-09 Combination therapy for treating hepatitis virus infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57119604P 2004-05-13 2004-05-13
US57122704P 2004-05-13 2004-05-13
US60/571,227 2004-05-13
US60/571,196 2004-05-13

Publications (2)

Publication Number Publication Date
WO2005110455A2 WO2005110455A2 (en) 2005-11-24
WO2005110455A3 true WO2005110455A3 (en) 2007-12-21

Family

ID=35394669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016353 WO2005110455A2 (en) 2004-05-13 2005-05-09 Combination therapy for treating hepatitis virus infection

Country Status (2)

Country Link
CA (1) CA2566677A1 (en)
WO (1) WO2005110455A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CN103635196B (en) 2011-03-02 2019-05-07 J·深塔格 For fatty degeneration of liver or treatment to be used individually with adipohepatic composition, treatment method and the diagnostic method of infection with hepatitis C virus
WO2013024157A2 (en) * 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
CN114262344A (en) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 Charged linkers and their use in conjugation reactions
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
LT3691620T (en) 2017-10-05 2022-09-26 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
WO2020132409A1 (en) * 2018-12-20 2020-06-25 Trustees Of Boston University Stk19 inhibitors for treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BORSCH-HAUBOLD ET AL.: "Identification of the phosphorylation sites of cytosolic phospholipase A2 in agonist-stimulated human platelets and HeLa cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 8, 1998, pages 4449 - 4458 *
BUREAU ET AL.: "Nonstructural 3 Protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 25, 2001, pages 23077 - 23083 *
DIAO ET AL.: "X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK Pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 11, 2001, pages 8328 - 8340 *
NAVARRO ET AL.: "p38-Dependent activation of interferon regulatory factor 3 by lipopolysaccharide", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 50, 1999, pages 35535 - 35538 *

Also Published As

Publication number Publication date
WO2005110455A2 (en) 2005-11-24
CA2566677A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2006016930A3 (en) Methods for treating hcv infection
Klebanoff et al. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost‐effectiveness analysis
WO2005110455A3 (en) Combination therapy for treating hepatitis virus infection
Loustaud-Ratti et al. Ribavirin: Past, present and future
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
Deutsch et al. Old and emerging therapies in chronic hepatitis C: an update
Mangia et al. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies
AP2313A (en) Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.
WO2005067454A3 (en) Combination therapy for treating hepatitis c virus infection
WO2006130627A3 (en) Methods for treating hepatitis c
WO2005013917A3 (en) Combination therapy for treating alphavirus infection and liver fibrosis
WO2006072624A3 (en) Compositions and methods for treating viral infection
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A3 (en) Anti-viral compounds
WO2007076035A3 (en) Anti-viral compounds
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004000858A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
EP2374464A3 (en) HCV N3S-NS4A protease inhibition
WO2003026589A3 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
WO2006096285A3 (en) Compositions and methods for treating or preventing flaviviridae infections
WO2006130553A3 (en) Hcv protease inhibitors
WO2010039801A3 (en) Methods of treating hepatitis c virus infection
NO20080351L (en) Use of songlifehrin in HCV

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2566677

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase